FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224256323> ?p ?o ?g. }

• W4224256323 endingPage "463" @default.
• W4224256323 startingPage "462" @default.
• W4224256323 abstract "Muscle tissue is composed of elongated and multinucleated contractile cells that reside within a highly organized connective tissue matrix. Muscle fibers are enveloped by a membrane termed the sarcolemma, in which are embedded proteins with structural and signaling roles. Myopathies are so called because they result in muscular weakness caused by dysfunction of diverse constituents of this highly specialized system.1Dowling J.J. Weihl C.C. Spencer M.J. Molecular and cellular basis of genetically inherited skeletal muscle disorders.Nat. Rev. Mol. Cell Biol. 2021; 22: 713-732https://doi.org/10.1038/s41580-021-00389-zCrossref PubMed Scopus (18) Google Scholar A large group of muscle diseases, termed muscular dystrophies, of which the best known is Duchenne muscular dystrophy (DMD), are monogenic diseases caused by numerous autosomal dominant, recessive, and X-linked mutations that predominantly affect muscle-protein-encoding genes. The SGC genes encode the sarcoglycan protein complex that is embedded in the sarcolemma and are mutated in limb girdle muscular dystrophy (LGMD). Although individually rare, when considered together, there is a large unmet clinical need, as available treatments do not reverse progressive muscle weakness. In a proof-of-principle study, Stadelmann et al. bring the potential of gene editing to restore muscle function caused by mutations in sarcolemmal proteins a step closer. By using messenger RNA as a platform to deliver the gene-editing effectors into cells, very high rates of gene correction were achieved that avoided the safety concerns of plasmid-mediated delivery. In future, to inform clinical trials, further studies using suitable animal models are needed to test whether gene-corrected muscle cells provide enduring reversibility of muscle weakness. Skeletal muscle contains normally quiescent skeletal muscle stem cells, also termed satellite cells, that reside adjacent to the sarcolemma. In a process that recapitulates embryonic development, satellite cells undergo asymmetric division to replace terminally differentiated muscle fibers that are damaged in muscular dystrophies and other myopathies. Concurrently, this mode of cell division serves to replenish the pool of stem cells. Satellite cells can be obtained from muscle biopsies, a relatively simple procedure, and then readily expanded ex vivo. These cells are endowed with superior repair properties compared with muscle progenitors derived from current in vitro human-induced pluripotent stem cell (hiPSC) differentiation protocols.2Xi H. Langerman J. Sabri S. Chien P. Young C.S. Younesi S. Hicks M. Gonzalez K. Fujiwara W. Marzi J. et al.A human skeletal muscle atlas identifies the trajectories of stem and progenitor cells across development and from human pluripotent stem cells.Cell Stem Cell. 2020; 27: 181-185https://doi.org/10.1016/j.stem.2020.06.006Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar Novel gene therapies and related treatments have started to become available for muscular dystrophies, but they still depend on endogenous mechanisms of satellite cell repair. Gene silencing using antisense oligonucleotides signaled the advent of gene therapies for muscular dystrophies, exemplified by the archetypal disease, DMD.3Hanson B. Wood M.J.A. Roberts T.C. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.RNA Biol. 2021; 18: 1048-1062https://doi.org/10.1080/15476286.2021.1874161Crossref PubMed Scopus (10) Google Scholar A drawback of the latter approach is the modest therapeutic effect and frequent dosing that is required. Alongside antisense oligos, viral-mediated gene-replacement therapy has received approval by the US Food and Drug Administration (FDA) for the treatment of another form of muscle weakness, spinal muscular atrophy (SMA). However, this procedure potentially has greater risks, and comprehensive data on the long-term safety of using viral vectors, commonly adeno-associated viral (AAV) vectors, will take time to gather.4Maurya S. Sarangi P. Jayandharan G.R. Safety of Adeno-associated virus-based vector-mediated gene therapy—impact of vector dose.Cancer Gene Ther. 2022; https://doi.org/10.1038/s41417-021-00413-6Crossref PubMed Scopus (1) Google Scholar A third strategy aims to prevent the degradation of mRNAs that harbor premature STOP codons through nonsense-mediated decay (NMD). In DMD, the truncated mutant protein products are partially functional and so this mechanism contributes significantly to the deficiency of the DMD gene product, dystrophin. Small-molecule drugs that interfere with NMD have been approved for the treatment of DMD in the European Union.5McDonald C.M. Campbell C. Torricelli R.E. Finkel R.S. Flanigan K.M. Goemans N. Heydemann P. Kaminska A. Kirschner J. Muntoni F. et al.Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 390: 1489-1498https://doi.org/10.1016/S0140-6736(17)31611-2Abstract Full Text Full Text PDF PubMed Scopus (245) Google Scholar The monogenic nature of most muscular dystrophies makes this group of diseases amenable to CRISPR-Cas9 gene editing to correct causative genetic mutations.6van Essen M. Riepsaame J. Jacob J. CRISPR-cas gene perturbation and editing in human induced pluripotent stem cells.CRISPR J. 2021; 4: 634-655https://doi.org/10.1089/crispr.2021.0063Crossref PubMed Scopus (1) Google Scholar By installing permanent changes in the sequence of the affected gene, the hope is that this approach will eventually offer a lasting cure with a “one-off” treatment. Cas9 induces double-strand breaks in DNA at genomic sites targeted by a complementary guide RNA (gRNA). Repair of these double-strand breaks then ensues by non-homologous end-joining or homology-directed repair. A complementary approach targeting single nucleotides uses a modified version of Cas9 devoid of DNA-cutting activity as a component of DNA base editors. Adenine base editors can produce an A to G nucleotide change (T to C on the opposite strand) within a targeting window several nucleotides long. Delivery of the CRISPR or base editing effectors to cells or tissues is a key consideration. For human therapies, plasmid-mediated transfer is not an option because of the potential risks of insertional mutagenesis and biosafety. These adverse effects can be mitigated by delivering Cas9 as mRNA in a complex with gRNA. Moreover, the transient nature of Cas9 expression resulting from mRNA delivery reduces off-target genome editing. Stadelmann et al. used mRNA to encode an adenine base editor and introduced it into satellite cells from multiple donors ex vivo, with the aim of correcting a disease-causing point mutation in an SGC gene.7Trabelsi M. Kavian N. Daoud F. Commere V. Deburgrave N. Beugnet C. Llense S. Barbot J.C. Vasson A. Kaplan J.C. et al.Revised spectrum of mutations in sarcoglycanopathies.Eur. J. Hum. Genet. 2008; 16: 793-803https://doi.org/10.1038/ejhg.2008.9Crossref PubMed Scopus (71) Google Scholar To test their gene-editing approach, they first targeted a single nucleotide in the NCAM1 coding sequence achieving an on-target editing rate of 90%. They then targeted SGCA and reported a similar editing efficiency. In an earlier study, they could not detect off-target effects within the activity window of the base editor for this gene and for this cell type.8Escobar H. Krause A. Keiper S. Kieshauer J. Müthel S. de Paredes M.G. Metzler E. Kühn R. Heyd F. Spuler S. Base editing repairs an SGCA mutation in human primary muscle stem cells.JCI Insight. 2021; 6https://doi.org/10.1172/jci.insight.145994Crossref PubMed Scopus (7) Google Scholar Furthermore, satellite cells nucleofected with the base editor mRNA retained their viability and remained functionally intact, and high rates of on-target editing could be achieved without enrichment. Together with the relatively short duration in culture, this makes for an efficient protocol to obtain sufficient gene-corrected satellite cells for downstream use. These findings strengthen support for potential early-phase human clinical trials. The study of Stadelmann et al. contributes significantly to the groundwork needed to bring this technology into clinical trials. mRNA delivery of gene-editing effectors is clearly feasible, efficient, and safer than plasmid delivery. However, before this work can be extended in human clinical trials, a thorough unbiased evaluation of off-target effects will be necessary. Furthermore, data on the efficiency and specificity of correcting a broader range of mutations should be evaluated. From a translational viewpoint, important next steps are to leverage mammalian models of muscular dystrophies to determine the minimum number of gene-edited satellite cells that should be transplanted into damaged muscle to restore function. The relationship between functional improvement, the type of muscular dystrophy, and the targeted muscle will need to be determined. An improvement on the current step of culturing satellite cells ex vivo would be desirable, and to this end, the possibly complementary approach of in vivo base or gene editing could transform the therapeutic landscape. To realize this goal, better delivery systems are first needed. In this respect, lipid nanoparticles (LNPs) hold great potential. At present, however, LNP delivery systems have been tested successfully in compact organs, such as the liver, rather than in skeletal muscle.9Qiu M. Glass Z. Chen J. Haas M. Jin X. Zhao X. Rui X. Ye Z. Li Y. Zhang F. Xu Q. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3.Proc. Natl. Acad. Sci. U S A. 2021; 118 (e2020401118)https://doi.org/10.1073/pnas.2020401118Crossref Scopus (50) Google Scholar Targeting specific muscles, for example, proximal limb muscles, might be more appropriate in restoring important functions, such as ambulation. Beyond focusing on repair of muscle, a considerable therapeutic challenge is posed by multi-system involvement in muscular dystrophies. An exciting decade of translational research lies ahead, which should suggest the best gene therapeutic option to repair dystrophic skeletal muscle, with the treatment of DMD likely to be at the forefront. The author is supported by the UK Medical Research Council ( MR/V037730/1 )." @default.
• W4224256323 created "2022-04-26" @default.
• W4224256323 creator A5060132061 @default.
• W4224256323 date "2022-06-01" @default.
• W4224256323 modified "2023-09-30" @default.
• W4224256323 title "Messenger RNA brings gene editing a step closer to treat muscular dystrophies" @default.
• W4224256323 cites W2073783399 @default.
• W4224256323 cites W2735778907 @default.
• W4224256323 cites W3023229905 @default.
• W4224256323 cites W3123764843 @default.
• W4224256323 cites W3134798812 @default.
• W4224256323 cites W3156150586 @default.
• W4224256323 cites W3180164640 @default.
• W4224256323 cites W3202203791 @default.
• W4224256323 cites W4206755691 @default.
• W4224256323 cites W4246421608 @default.
• W4224256323 doi "https://doi.org/10.1016/j.omtn.2022.04.005" @default.
• W4224256323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35505962" @default.
• W4224256323 hasPublicationYear "2022" @default.
• W4224256323 type Work @default.
• W4224256323 citedByCount "0" @default.
• W4224256323 crossrefType "journal-article" @default.
• W4224256323 hasAuthorship W4224256323A5060132061 @default.
• W4224256323 hasBestOaLocation W42242563231 @default.
• W4224256323 hasConcept C104317684 @default.
• W4224256323 hasConcept C105580179 @default.
• W4224256323 hasConcept C21786251 @default.
• W4224256323 hasConcept C2779030066 @default.
• W4224256323 hasConcept C41008148 @default.
• W4224256323 hasConcept C54355233 @default.
• W4224256323 hasConcept C70721500 @default.
• W4224256323 hasConcept C86803240 @default.
• W4224256323 hasConceptScore W4224256323C104317684 @default.
• W4224256323 hasConceptScore W4224256323C105580179 @default.
• W4224256323 hasConceptScore W4224256323C21786251 @default.
• W4224256323 hasConceptScore W4224256323C2779030066 @default.
• W4224256323 hasConceptScore W4224256323C41008148 @default.
• W4224256323 hasConceptScore W4224256323C54355233 @default.
• W4224256323 hasConceptScore W4224256323C70721500 @default.
• W4224256323 hasConceptScore W4224256323C86803240 @default.
• W4224256323 hasLocation W42242563231 @default.
• W4224256323 hasLocation W42242563232 @default.
• W4224256323 hasLocation W42242563233 @default.
• W4224256323 hasOpenAccess W4224256323 @default.
• W4224256323 hasPrimaryLocation W42242563231 @default.
• W4224256323 hasRelatedWork W1991523530 @default.
• W4224256323 hasRelatedWork W2002128513 @default.
• W4224256323 hasRelatedWork W2009966535 @default.
• W4224256323 hasRelatedWork W2020824267 @default.
• W4224256323 hasRelatedWork W2031436818 @default.
• W4224256323 hasRelatedWork W2057739827 @default.
• W4224256323 hasRelatedWork W2075354549 @default.
• W4224256323 hasRelatedWork W2088063203 @default.
• W4224256323 hasRelatedWork W2171277769 @default.
• W4224256323 hasRelatedWork W2092874662 @default.
• W4224256323 hasVolume "28" @default.
• W4224256323 isParatext "false" @default.
• W4224256323 isRetracted "false" @default.
• W4224256323 workType "article" @default.